DR
DR6.F ACADIA Pharmaceuticals Inc
- Market cap
- EUR 2.81B
- P/E
- 10.7x
- P/B
- 2.19x
- ROE
- 8.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is DR6.F undervalued?
Graham numberDR6.F trades 2.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ACADIA Pharmaceuticals Inc fundamental analysis
No fundamental analysis for ACADIA Pharmaceuticals Inc yet.
ACADIA Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the sy…
Full company profileACADIA Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ACADIA Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 17.3M | 125M | 224M | 339M | 442M | 484M | 517M | 726M | 958M | 1.07B | 1.22B |
| Gross Profit | 12.9M | 112M | 205M | 319M | 421M | 465M | 507M | 685M | 876M | 983M | 1.11B |
| Operating Income | -273M | -292M | -247M | -247M | -287M | -170M | -224M | -73.4M | 84.3M | 105M | 140M |
| EBITDA | - | -290M | -244M | -244M | -284M | - | -222M | -67.8M | 100M | 117M | 153M |
| Net Income | -271M | -289M | -245M | -235M | -282M | -168M | -216M | -61.3M | 226M | 391M | 118M |
| EPS | - | -2.33 | -1.70 | -1.52 | -1.76 | -1.04 | -1.33 | -0.37 | 1.36 | 2.30 | 0.68 |
| Balance Sheet | |||||||||||
| Total Assets | 561M | 385M | 540M | 783M | 783M | 700M | 588M | 749M | 1.19B | 1.56B | 1.79B |
| Total Liabilities | 42.7M | 49.2M | 61.1M | 84.0M | 156M | 159M | 187M | 317M | 455M | 337M | 407M |
| Shareholders' Equity | 518M | 335M | 479M | 699M | 627M | 541M | 400M | 432M | 733M | 1.23B | 1.39B |
| Cash & Short-term Investments | 164M | 69.4M | 135M | 190M | 326M | 147M | 115M | 189M | 320M | 178M | 322M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -208M | -218M | -167M | -151M | -136M | -126M | -114M | 16.7M | 158M | 110M | 195M |
| Capital Expenditure | 9.51M | 812K | 2.10M | 1.13M | 7.59M | 1.12M | 0.00 | 50.0K | 523K | 4.69M | 15.4M |
| Free Cash Flow | - | -219M | -170M | -152M | -144M | -127M | -114M | 16.7M | 157M | 105M | 180M |
| Ratios | |||||||||||
| ROE | -52.4% | -86.3% | -51.2% | -33.7% | -44.9% | -31.0% | -53.9% | -14.2% | 30.9% | 31.9% | 8.5% |
| ROA | -48.4% | -75.3% | -45.4% | -30.0% | -36.0% | -24.0% | -36.7% | -8.2% | 19.1% | 25.0% | 6.6% |
| Net Profit Margin | -1,565.9% | -231.7% | -109.6% | -69.4% | -63.7% | -34.7% | -41.8% | -8.4% | 23.6% | 36.5% | 9.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ACADIA Pharmaceuticals Inc dividends
ACADIA Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Who owns ACADIA Pharmaceuticals Inc
- Insiders 0.33%
- Institutions 98.78%
- Public & others 0.89%
- Shares outstanding 173M
- Free float 129M
ACADIA Pharmaceuticals Inc company profile
- Company name
- ACADIA Pharmaceuticals Inc
- Ticker
- DR6.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 796
- Fiscal year end
- December
- Address
- 12830 El Camino Real, San Diego, CA, United States, 92130
- Phone
- 858 558 2871
- Website
- acadia.com
About ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
ACADIA Pharmaceuticals Inc management
10- Ms. Catherine E. Owen AdamsCEO & Director · born 1970
- Mr. Mark C. SchneyerExecutive VP & CFO · born 1974
- Ms. Jennifer J. Rhodes J.D.Executive VP, Chief Legal Officer & Secretary · born 1970
- Mr. Thomas Andrew GarnerExecutive VP & Chief Commercial Officer · born 1976
- Mr. Scott CenciSenior VP, Chief Information & Data Officer
- Mr. Albert S. KildaniSenior Vice President of Investor Relations & Corporate Communications
- Mr. Carl SegerstromChief People Officer
- Mr. James K. KiharaSenior Vice President of Finance · born 1981
- Ms. Allyson McMillan-YoungbloodSenior Vice President of Rare Disease Franchise
- Ms. Konstantina KatchevesSenior VP, Chief Business & Strategy Officer